Minimally Invasive Surgical Instruments Market

Minimally Invasive Surgical Instruments Market Size, Share & Trends

The size of global minimally invasive surgical instruments market in terms of revenue was estimated to be worth $31.7 Billion in 2024 and is poised to reach $49.9 Billion by 2029, growing at a CAGR of 9.5% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

The rising adoption of minimally invasive surgical procedures is a response to the growing volume of surgical interventions. These techniques are associated with fewer complications and shorter recovery times compared to open surgeries. Consequently, the escalating number of surgeries worldwide is driving the heightened demand for minimally invasive surgical instruments.

Minimally Invasive Surgical Instruments Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Minimally Invasive Surgical Instruments Market Dynamics

Driver: Advantages of MIS over open surgical techniques

In recent years, minimally invasive surgeries (MIS) have experienced significant technological advancements, revolutionizing the landscape of surgical procedures in operating rooms. Surgeons increasingly favor advanced MIS techniques such as laparo-endo single-incision surgery (LESS) due to their numerous advantages over traditional open surgical methods. These benefits encompass reduced scarring and tissue damage, expedited recovery times, shorter hospital stays, decreased blood loss and trauma, lower infection risks, and overall cost savings in healthcare. Furthermore, select health insurance providers in certain countries are expanding coverage for minimally invasive surgeries, further fueling patient preference for these procedures.

Restraint: Changing regulatory landscape in the medical device industry

The US FDA now requires more extensive clinical data regarding the safety and efficacy of products. Consequently, companies must invest more in clinical trials, resulting in approval delays and increased capital requirements for thorough post-marketing surveillance studies. Moreover, the risk of product recalls rises, especially for companies lacking funds to conduct additional studies to meet the FDA's data requirements. These approval delays significantly impede the growth of the market.

Opportunity: Increasing adoption of advanced robotics in ASCs

Ambulatory surgery centers (ASCs) are independent facilities specializing in surgical, diagnostic, and preventive procedures that do not necessitate hospital admission. The cost-effectiveness of ASCs yields significant savings for governments, third-party payers, and patients. A joint study by Healthcare BlueBook, a provider of healthcare services data, and HealthSmart, a provider of health plans for self-funded employers, determined that ASCs annually reduce the cost of outpatient surgery by USD 38 billion. This reduction stems from ASCs offering a more cost-effective site of care compared to hospital outpatient departments. Consequently, ASCs, particularly in the US, are increasingly adopting advanced robotics to manage complex cases.

Challenge: High degree of market consolidation

A significant level of consolidation exists among market players, with only major companies capable of affording substantial capital investments and the high costs associated with research and development, as well as manufacturing. This scenario acts as a barrier to entry for new participants attempting to enter the market. Newcomers need to vie against established competitors and differentiate themselves by creating innovative products.

The instruments market is moderately consolidated. The top players— Medtronic PLC (US), Johnson & Johnson (US), Intuitive Surgical Inc. (US), Boston Scientific Corporation (US), Stryker Corporation (US), Abbott Laboratories, Inc. (US), B. Braun SE (Germany), Conmed Corporation (US), Smith + Nephew (UK), Zimmer Biomet Holdings, Inc. (US), Becton, Dickinson and Company (US), The Cooper Companies Inc. (US), Surgical Innovations Group PLC(UK), Koninklijke Philips N.V. (Netherlands), FUJIFILM Holdings Corporation(Japan) in the market accounted for a combined majority market share in 2023. The companies in the sector are fiercely competitive.

Genotyping assay Ecosystem/Market Map

In 2023, handheld instruments segment of the minimally invasive surgical instruments industry accounted for the highest CAGR

The minimally invasive surgical instruments market is mainly divided into into handheld instruments, inflation devices, surgical scopes, cutting instruments, guiding devices, electrosurgical & electrocautery instruments, robotic instruments and other instruments. In 2023, the handheld instruments held the highest share. The limited maneuverability of conventional manual laparoscopic instruments in minimally invasive surgery presents challenges during surgical procedures. As a result, there has been a push for the advancement of articulating laparoscopic surgical instruments that offer improved dexterity at a lower cost. These technological innovations in handheld instruments are contributing significantly to the growth of the market.

In 2023, The robotic surgery segment of the minimally invasive surgical instruments industry is accounted for highest CAGR

By technology, the minimally invasive surgical instruments market is primarily segmented into non-robotic surgery and robotic surgery. In 2023, robotic surgery accounted for the highest CAGR of this market. The benefits of robotic surgery, such as reduced trauma, faster recovery times, and improved outcomes, have led to greater adoption across various surgical specialties. Furthermore, the growing investment in healthcare infrastructure and the rising prevalence of chronic diseases requiring surgical interventions have fueled the demand for robotic MIS procedures. Lastly, favorable reimbursement policies and increased awareness among healthcare professionals and patients about the advantages of robotic surgery have further accelerated its adoption, resulting in the highest CAGR within the MIS market segment.

In 2023, Cardiothoracic segment of the minimally invasive surgical instruments industry is accounted for the highest share

By Type of Surgery, the minimally invasive surgical instruments market is primarily segmented into cardiothoracic surgery, gastrointestinal surgery, orthopedic surgery, gynecological surgery, cosmetic & bariatric surgery, urological surgery, and other surgeries. The cardiothoracic surgery segment accounted for the largest share of the market in 2023. Minimally invasive cardiothoracic procedures present numerous benefits compared to traditional methods, including decreased surgical trauma, lower blood loss, reduced infection risks, shorter hospital stays (typically 3–5 days), and quicker recovery times (around 2–4 weeks). The increasing occurrence of cardiac disorders serves as a significant driver for the expansion of the cardiothoracic surgery segment. Moreover, with the growing patient population, there's a heightened adoption of advanced technologies for cardiovascular surgeries, which is anticipated to bolster the market growth in this segment.

In 2023, Hospitals and specialty clinics segment of the minimally invasive surgical instruments industry is accounted for the highest share

By end user, the minimally invasive surgical instruments market is primarily segmented into hospitals and specialty clinics and ambulatory surgery centers. The hospitals and specialty clinics segment accounted for a larger share of the market in 2023. Hospitals and specialty clinics stand out as the largest end-user segment within the minimally invasive surgical (MIS) instruments market, primarily due to their execution of intricate diagnostic and therapeutic procedures. These facilities boast superior testing capabilities, streamlined billing processes, state-of-the-art MIS instrumentation, and cost-effective testing services. Consequently, the prevalence of minimally invasive surgical instruments is notably higher in hospitals and specialty clinics, attributed to their robust purchasing capacity, proficient healthcare workforce, and access to advanced surgical facilities.

North America is the largest regional market for minimally invasive surgical instruments industry

The global minimally invasive surgical instruments market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America held the most market share for minimally invasive surgical instruments worldwide in 2023. The expansion of the North American market may be ascribed to the relationship between rising population and rising awareness of MIS.

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Medtronic PLC (US), Johnson & Johnson (US), Intuitive Surgical Inc. (US), Boston Scientific Corporation (US), Stryker Corporation (US). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Minimally Invasive Surgical Instruments Industry

This report categorizes the minimally invasive surgical instruments market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Handheld Instruments
  • Graspers
  • Retractors/Elevators
  • Suturing Instruments
  • Dilators
  • Other Handheld Instruments
• Inflation Devices
  • Balloons
  • Balloon Inflation Devices
• Surgical Scopes
  • Laparoscopes
  • Urology Endoscopes
  • Arthroscopes
  • Neuroendoscopes
  • Other Surgical Scopes
• Cutting Instruments
  • Trocars
  • Other Cutting Instruments
• Guiding Devices
  • Guiding Catheters
  • Guidewires
• Electrosurgical & Electrocautery Instruments
  • Electrosurgical Instruments
  • Electrocautery Devices
• robotic instruments
• Other Instruments

By Technology

• Non-robotic Surgery
• Robotic Surgery

By Type of Surgery

• Cardiothoracic Surgery
• Gastrointestinal Surgery
• Orthopedic Surgery
• Gynecological Surgery
• Cosmetic & Bariatric Surgery
• Urological Surgery
• Other Surgeries

By End User

• Hospitals and Specialty Clinics
• Ambulatory Surgery Centers

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East Africa
• GCC Countries

Recent Developments of Minimally Invasive Surgical Instruments Industry:

• In May 2024, Intuitive received FDA clearance for the fifth-generation robotic system, da Vinci 5.
• In January 2024, Boston Scientific Corporation entered into an agreement to acquire Axonics, Inc. This will enable the company’s entry into sacral neuromodulation, a high-growth adjacency with opportunities to expand patients' access to care.
• In November 2023, Medtronic received approval from the United States Food and Drug Administration (FDA) for the Symplicity Spyral renal denervation (RDN) system, also known as the Simplicity blood pressure procedure, for the treatment of hypertension.
• In November 2023, Johnson & Johnson MedTech announced that the MONARCH Platform and MONARCH Bronchoscope have received regulatory approval in China.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst